Abstract
Introduction: Identification of an eosinophilic (EOS) phenotype in obstructive lung disease is important for disease management. The International Severe Asthma Registry (ISAR) proposes EOS Grades, a classification based on blood eosinophil count and clinical characteristics.
Aim: To describe and characterise the ISAR EOS Grades in patients with asthma and/or COPD from NOVELTY.
Methods: NOVELTY (NCT02760329) is a global, observational study of patients with physician-assigned diagnosis of asthma and/or COPD. The ISAR EOS Grades classify patients as Grades 0 to 3 (Grade 0=unlikely/non-eosinophilic to Grade 3=most likely eosinophilic; figure).
Results: Of 4,877 patients with available baseline data, Grade 3 was found in 29% overall and 37%, 29% and 17% of patients with asthma (N=2,605), asthma+COPD (N=630) and COPD (N=1,642), respectively. The frequency of Grade 3 increased with physician-assessed severity for asthma and asthma+COPD, but not COPD. For all diagnoses, the mean exacerbation rate in the past 12 months was higher among Grade 3 (1.02, overall) vs Grades 0–2 (0.75–0.84, overall). For asthma and asthma+COPD, but not COPD, there was greater airflow obstruction and poorer quality of life among Grade 3 vs Grades 0–2.
Conclusion: ISAR-defined EOS Grade 3 was prevalent in patients with asthma and/or COPD and was associated with higher physician-assessed severity and exacerbation rate.
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3705.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021
